<SEC-DOCUMENT>0001193125-23-250305.txt : 20231004
<SEC-HEADER>0001193125-23-250305.hdr.sgml : 20231004
<ACCEPTANCE-DATETIME>20231004060500
ACCESSION NUMBER:		0001193125-23-250305
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231004
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231004
DATE AS OF CHANGE:		20231004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		231306533

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d547410d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:teva="http://tevapharm.com/20231004" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-10-04_to_2023-10-04">TEVA PHARMACEUTICAL INDUSTRIES LTD</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-04_to_2023-10-04">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-04_to_2023-10-04">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-04_to_2023-10-04">0000818686</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="teva-20231004.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-04_to_2023-10-04"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-04</xbrli:startDate> <xbrli:endDate>2023-10-04</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-04_to_2023-10-04">8-K</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported) <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt:datemonthdayyearen">October&#160;4, 2023</ix:nonNumeric></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrants as specified in its charter)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-04_to_2023-10-04">001-16174</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not Applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation))</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-04_to_2023-10-04">124 Dvora Hanevi&#8217;a Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-04_to_2023-10-04">Tel Aviv</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-04_to_2023-10-04">6944020</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices, including Zip Code)</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-04_to_2023-10-04">+972</ix:nonNumeric><span style="white-space:nowrap">-</span> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-04_to_2023-10-04">3-914-8213</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, including Area Code)</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Copies of communications to:</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-04_to_2023-10-04">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-04_to_2023-10-04">TEVA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging Growth Company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-04_to_2023-10-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">ITEM&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;4, 2023, Teva Pharmaceutical Industries Ltd. (the &#8220;Company&#8221;) issued a press release announcing its entry into an exclusive collaboration with Sanofi to <span style="white-space:nowrap">co-develop</span> and <span style="white-space:nowrap">co-commercialize</span> Teva&#8217;s <span style="white-space:nowrap">TEV-48574</span> asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn&#8217;s disease, two types of inflammatory bowel disease. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the &#8220;Commission&#8221;) and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) nor shall it be deemed incorporated by reference in any filing made by the Company under the&#160;Securities Act&#160;or the Exchange Act, except as set forth by specific reference in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the collaboration agreement contain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#8217;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and other words and terms of similar meaning and expression. Important factors that could cause or contribute to such differences include risks relating to: our exclusive collaboration with Sanofi, including uncertainties around the effective date of the collaboration and our ability to satisfy the closing conditions related thereto; risks related to the timing of and our ability to achieve expected results for <span style="white-space:nowrap">TEV-48574</span> (anti-TL1A), including our ability to commercialize <span style="white-space:nowrap">TEV-48574</span> (anti-TL1A); the extent to which we will realize the anticipated financial and other benefits of the Sanofi collaboration; our ability to satisfy the conditions to receiving milestone cash payments under the Sanofi collaboration agreement; the risk that we will incur significant costs in connection with the development of <span style="white-space:nowrap">TEV-48574</span> (anti-TL1A), which may exceed any revenue generated by <span style="white-space:nowrap">TEV-48574</span> (anti-TL1A); risks that regulatory approvals and other requirements may delay the development and commercialization of <span style="white-space:nowrap">TEV-48574</span> (anti-TL1A); our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, our ability to successfully launch and execute our new Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and the effectiveness of our patents and other measures to protect our intellectual property rights; our business and operations in general, including, the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and costs and delays resulting from the extensive pharmaceutical regulation to which we are subject. Investors should read the important risk factors described in the Company&#8217;s most recent Annual Report on <span style="white-space:nowrap">Form&#160;10-K,&#160;Quarterly</span> Report on <span style="white-space:nowrap">Form&#160;10-Q&#160;and</span> Current Reports on <span style="white-space:nowrap">Form&#160;8-K&#160;filed</span> with the Commission. Forward-looking statements speak only as of the date on which they are made, and the Company assumes no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. Investors are cautioned not to put undue reliance on these forward-looking statements. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">ITEM&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span><br /><span style="font-weight:bold">No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description of Document</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d547410dex991.htm">Press release of the Company issued on October&#160;4, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;4, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Eli Kalif</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, Chief Financial Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d547410dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1&#8194; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Press Release</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g547410img001.jpg" ALT="LOGO">
&#8194;</TD></TR>
</TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:0%" ALIGN="right">


<IMG SRC="g547410img002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TEV &#145;574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn&#146;s disease
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collaboration supports Sanofi&#146;s immunology strategy of exploring novel mechanisms of action for chronic
inflammatory diseases </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collaboration leverages the innovative R&amp;D and commercial expertise of both companies </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paris, France and Parsippany, New Jersey, October</B><B></B><B>&nbsp;4, 2023</B>. Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S.
subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> asset TEV &#145;574, currently
in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn&#146;s Disease, two types of inflammatory bowel disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Paul Hudson </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Chief
Executive Officer, Sanofi </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Anti-TL1As are a promising class of therapies, and we believe that TEV &#145;574 could emerge as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for
inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Richard
Francis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer, Teva </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further
validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with
our capabilities to optimize development and global launches.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the new collaboration agreement, Teva will receive an upfront
payment of &#128;469&nbsp;million ($500 million) and up to &#128;940&nbsp;million ($1&nbsp;billion) in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets,
with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization
in North America, Japan, other parts of Asia and the rest of the world. The transaction will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inflammatory bowel disease (IBD) is the term for two conditions &#150; Crohn&#146;s disease and ulcerative colitis &#150; characterized by chronic
inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated
~10&nbsp;million people worldwide live with IBD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teva Investor Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva will hold an investor call and live webcast today (Wednesday, October&nbsp;4, 2023) at 8:00 a.m. ET to discuss this collaboration. To participate, please
register in advance <B><U>here</U></B> to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva&#146;s website at:
<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ir.tevapharm.com/Events-and-Presentations</FONT></FONT></U>. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Sanofi
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team,
across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people
globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Teva </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve people&#146;s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic
area. Around 200&nbsp;million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have
significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi Media Relations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sally Bain </B>| + 1 617 834
6026 | <U>sally.bain@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sandrine Guendoul </B>| + 33 6 25 09 14 25 | <U>sandrine.guendoul@sanofi.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 |<U>&nbsp;victor.rouault@sanofi.com</U> </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi Investor Relations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eva
Schaefer-Jansen</B><B></B>&nbsp;|&nbsp;+ 33 7 86 80 56 39 |&nbsp;<U>eva.schaefer-jansen@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arnaud Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+
33 6 73 69 36 93 | <U>arnaud.delepine@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corentine Driancourt</B><B></B>&nbsp;|&nbsp;+ 33 6 40 56 92 21 |
<U>corentine.driancourt@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <U>felix.lauscher@sanofi.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tarik Elgoutni|</B> + 1 617 710 3587 | <U>tarik.elgoutni@sanofi.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 | <U>nathalie.pham@sanofi.com</U> </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Teva Investor Relations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ran Meir </B>| (267) <FONT
STYLE="white-space:nowrap">468-4475</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Yael Ashman </B>| +972 (3) 914 8262 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sanjeev Sharma </B>| (973) <FONT STYLE="white-space:nowrap">524-1908</FONT> </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Teva Corporate Affairs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kelley Dougherty </B>| (973) <FONT
STYLE="white-space:nowrap">658-0237</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eden Klein </B>| +972 (3) 906 2645 </P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sanofi Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s
management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks
and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and
when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product
candidates, the fact that product candidates if approved may not be commercially successful, the future approval and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2/3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our
employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148;
and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022. Other than as required by applicable law, Sanofi
does not undertake any obligation to update or revise any forward-looking information or statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teva Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on
management&#146;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or
implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148;
&#147;project,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such differences include: risks relating to our exclusive collaboration with Sanofi, including uncertainties around the effective date of the collaboration and our ability to satisfy the closing
conditions related thereto; risks related to the timing of and our ability to achieve expected results for <FONT STYLE="white-space:nowrap">TEV-48574</FONT> (anti-TL1A), including our ability to commercialize
<FONT STYLE="white-space:nowrap">TEV-48574</FONT> (anti-TL1A); the extent to which we will realize the anticipated financial and other benefits of the Sanofi collaboration; our ability to satisfy the conditions to receiving milestone cash payments
under the Sanofi collaboration agreement; the risk that we will incur significant costs in connection with the development of <FONT STYLE="white-space:nowrap">TEV-48574</FONT> (anti-TL1A), which may exceed any revenue generated by <FONT
STYLE="white-space:nowrap">TEV-48574</FONT> (anti-TL1A); risks that regulatory approvals and other requirements may delay the development and commercialization of <FONT STYLE="white-space:nowrap">TEV-48574</FONT> (anti-TL1A); our ability to
successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our innovative medicines, including AUSTEDO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, AJOVY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and COPAXONE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize
additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our ability to successfully launch and execute our new Pivot to Growth strategy, including to expand our
innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our
substantial indebtedness which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow
funds in amounts or on terms that are favorable to us; our business and operations in general, including, the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and costs
and delays resulting from the extensive pharmaceutical regulation to which we are subject; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks;
and other factors discussed in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the second quarter of 2023 and in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022, including in the section captioned &#147;Risk Factors.&#148; Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other
information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3/3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>teva-20231004.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/4/2023 9:24:46 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:teva="http://tevapharm.com/20231004"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://tevapharm.com/20231004"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20231004_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20231004_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>teva-20231004_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/4/2023 9:24:46 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>teva-20231004_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/4/2023 9:24:46 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="teva-20231004.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g547410img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g547410img001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M>C:A#=Q#AMA^9#Z,IY'XT :U &/XA\4Z)X5L_M6M:A%:1G[H8Y9_]U1R?PH
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MQY5@V"1E3[ ]Z .C_9P9AX\U%03M.G,2.W^LCH Z?]I<D:7X>7)QYTQQ^"T
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M .#_ &</^1^U'_L&O_Z,CH Z?]I?_D&^'?\ KK-_)* (?V9O]5XF^MM_[4H
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M3E2/PX^H- 'KW@3X^Z?9Z#;Z=XHBN?M-L@C2YA7>)% P-PSD-[\YH Y_XO\
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A "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g547410img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g547410img002.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MIN,[]&8VEZL/^$6U1I<F1&B!'][DXISH/GM'9G \.[24=G8A\(:3<>)M?^R
MG]X0TK_W$'4_T'X5==*"21U4Z5VH1/3?BSH/VCPA;7%I'QIK#Y1VC(VG\L+6
M>&E:5GU.^O#W-.AY-X2\12>%_$,&I*ADC&4EC'5D/4?7H?PKMJ0YXV.2G/DE
M<]^L_'/AF]LUN4UJUC4C)2:0(X]BIYKS72FG:QZ"JP:O<\L^)GCNV\0B+2M+
M8O90OYDDI&/,;H,#T&3]?PKLH4G#WI;G)7JJ7NK8H_"7_D?(/^N,G\JK$?PR
M</\ &?05>:>B% &#XM\,6WBO1'L9F\N53OAEQG8W^'8UI3J.G*Z,ZD%.-CPC
M5? 'B72)F232YIT!XEME,BD>O'(_$"O0C6A+J<$J4X]!NA^&_%0U2WN--TJ\
MCN(7#I(\115(]2V!3E.%K-A&$[W2/5O&GPZ_X2>*/4;=HK76?+ E'/ERD#H3
MUR.@/YUQTJW)H]CKJ4>?5;GD=_X+\2:9*4N-&NC@_>BC,BG\5R*[%5@]F<;I
MSCNB73? OB;5)52'2+B-3_'.AC4?BV/THE5A'J$:4WLCVWP)X0?PAI4L$UXU
MQ/.P>0+_ *M"!_"/YGO@5P5:GM&=U*G[-6-K7-%M/$&D3Z;>KF*4<,.J-V8>
MXK.$G!W1I**DK,\+E\&:[IEEK>GG3KB=DEA"/%&2L@RV"OKU'T[UZ"JQ;3N<
M'LY135CUGP%X/C\*:,!*%;4;@!KAQSCT0>P_4UQUJG/+R.NE3Y%YG4RQ1S1/
M%*BO&ZE65AD$'J#6.QL>*^+/A+?6ES)=>'U^TVC'/V<MB2/V&?O#]?KUKOIX
MA-6D<-3#M:Q.&/AG7A-Y)T6_\S.-OV9\_P JZ.>/<PY)=C:?X:^)H](%\VGN
M7:0*MLOS28()W$#H. /7FL_;PO:Y?L9I7L=!\-/"^N:7XRANK[2[BW@6)P7D
M3 R1Q6=>I%PLF:4(2C.[1[97 =P4 % !0 4 % !0 4 % !0 4 % !0 4 % !
E0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140509428714144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LTD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  04,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora Hanevi&#8217;a Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-914-8213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d547410d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="teva-20231004.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-04_to_2023-10-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-10-04_to_2023-10-04"
      id="Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LTD</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2023-10-04_to_2023-10-04"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2023-10-04_to_2023-10-04">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-04_to_2023-10-04"
      id="Hidden_dei_EntityCentralIndexKey">0000818686</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-10-04_to_2023-10-04">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-04_to_2023-10-04">2023-10-04</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-04_to_2023-10-04">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-04_to_2023-10-04">001-16174</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-04_to_2023-10-04">124 Dvora Hanevi&#x2019;a Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-04_to_2023-10-04">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-04_to_2023-10-04">6944020</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2023-10-04_to_2023-10-04">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="duration_2023-10-04_to_2023-10-04">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-04_to_2023-10-04">3-914-8213</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-04_to_2023-10-04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-04_to_2023-10-04">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-04_to_2023-10-04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-04_to_2023-10-04">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-04_to_2023-10-04">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-04_to_2023-10-04">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-04_to_2023-10-04">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-04_to_2023-10-04">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )TP1%<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "=,$17&(N,ZN\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:2=(J'+BV-/"H(#Q;>0W+9@TX;DI-VW-ZU;A^@'\#%W__SN
M=W"-"=+T$9]C'S"2PW0S^K9+TH0U.Q(%"9#,$;U.94YTN;GOH]>4G_$ 09L/
M?4"H.+\#CZ2M)@T3L @+D:G&&FDB:NKC&6_-@@^?L9UAU@"VZ+&C!*(4P-0T
M,9S&MH$K8((11I^^"V@7XES]$SMW@)V38W)+:AB&<JCG7-Y!P-O3X\N\;N&Z
M1+HSF'\E)^D4<,TNDU_KA\UNRU3%J[H0O."KG>"2K^3M_?OD^L/O*NQ[Z_;N
M'QM?!%4#O^Y"?0%02P,$%     @ G3!$5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " "=,$17EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( )TP1%<<.&7J/P$
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M?P%02P$"% ,4    " "=,$17!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )TP1%<8BXSJ[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( )TP1%>97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ G3!$5ZZ!=?-H!   N1   !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( )TP1%>?H!OPL0(  .(,   -              "  :P,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ G3!$5Y>*NQS     $P(   L
M ( !B \  %]R96QS+RYR96QS4$L! A0#%     @ G3!$5QPX9>H_ 0  / (
M  \              ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M )TP1%<D'INBK0   /@!   :              "  =T1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )TP1%=ED'F2&0$  ,\#   3
M              "  <(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(   P4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d547410d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d547410d8k.htm">d547410d8k.htm</File>
    <File>teva-20231004.xsd</File>
    <File>teva-20231004_lab.xml</File>
    <File>teva-20231004_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d547410d8k.htm": {
   "nsprefix": "teva",
   "nsuri": "http://tevapharm.com/20231004",
   "dts": {
    "inline": {
     "local": [
      "d547410d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "teva-20231004.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20231004_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20231004_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2022": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "report": {
    "R1": {
     "role": "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-04_to_2023-10-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d547410d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-04_to_2023-10-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d547410d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tevapharm.com//20231004/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-250305-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-250305-xbrl.zip
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M1=HL7-KH#-&S*:,>TT#E-E#BAS2EL[5(F0]Z,)E;.W;("V!:!OU$0F<E(_;
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M3D/DB<N2&S4D^>20P<4O2I#3_NX0-D =K+UC/YV]H'XA:1 DD=($I-:PQ.H
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MCX;B_[9W&3<>JZL<K-&?1L5#_HNJ_PM02P,$%     @ G3!$5],?9AT_ P
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M-S0Q,&0X:RYH=&U02P$"% ,4    " "=,$17VE:REXD8  !850  $0
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7;%!+!08     !0 % $ !  #./      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
